MEDICAL FACILITIES CORP (DR.CA) Fundamental Analysis & Valuation

TSX:DR • CA58457V5036

Current stock price

17.06 CAD
+0.19 (+1.13%)
Last:

This DR.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. DR.CA Profitability Analysis

1.1 Basic Checks

  • In the past year DR was profitable.
  • In the past year DR had a positive cash flow from operations.
  • DR had positive earnings in 4 of the past 5 years.
  • In the past 5 years DR always reported a positive cash flow from operatings.
DR.CA Yearly Net Income VS EBIT VS OCF VS FCFDR.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M

1.2 Ratios

  • DR's Return On Assets of 7.80% is amongst the best of the industry. DR outperforms 84.62% of its industry peers.
  • DR's Return On Equity of 28.17% is amongst the best of the industry. DR outperforms 100.00% of its industry peers.
  • The Return On Invested Capital of DR (19.99%) is better than 100.00% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for DR is significantly above the industry average of 6.93%.
  • The last Return On Invested Capital (19.99%) for DR is above the 3 year average (17.04%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.8%
ROE 28.17%
ROIC 19.99%
ROA(3y)11.41%
ROA(5y)7.31%
ROE(3y)36.64%
ROE(5y)23.18%
ROIC(3y)17.04%
ROIC(5y)16.99%
DR.CA Yearly ROA, ROE, ROICDR.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

1.3 Margins

  • Looking at the Profit Margin, with a value of 8.36%, DR belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
  • In the last couple of years the Profit Margin of DR has grown nicely.
  • The Operating Margin of DR (18.36%) is better than 100.00% of its industry peers.
  • In the last couple of years the Operating Margin of DR has grown nicely.
  • DR has a better Gross Margin (69.88%) than 100.00% of its industry peers.
  • In the last couple of years the Gross Margin of DR has remained more or less at the same level.
Industry RankSector Rank
OM 18.36%
PM (TTM) 8.36%
GM 69.88%
OM growth 3Y8.16%
OM growth 5Y9.83%
PM growth 3YN/A
PM growth 5Y28.17%
GM growth 3Y1.88%
GM growth 5Y0.92%
DR.CA Yearly Profit, Operating, Gross MarginsDR.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. DR.CA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DR is creating value.
  • Compared to 1 year ago, DR has less shares outstanding
  • DR has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for DR is higher compared to a year ago.
DR.CA Yearly Shares OutstandingDR.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
DR.CA Yearly Total Debt VS Total AssetsDR.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • DR has an Altman-Z score of 1.48. This is a bad value and indicates that DR is not financially healthy and even has some risk of bankruptcy.
  • With a decent Altman-Z score value of 1.48, DR is doing good in the industry, outperforming 61.54% of the companies in the same industry.
  • The Debt to FCF ratio of DR is 2.47, which is a good value as it means it would take DR, 2.47 years of fcf income to pay off all of its debts.
  • DR's Debt to FCF ratio of 2.47 is amongst the best of the industry. DR outperforms 92.31% of its industry peers.
  • A Debt/Equity ratio of 1.18 is on the high side and indicates that DR has dependencies on debt financing.
  • With a Debt to Equity ratio value of 1.18, DR perfoms like the industry average, outperforming 46.15% of the companies in the same industry.
  • Although DR's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 1.18
Debt/FCF 2.47
Altman-Z 1.48
ROIC/WACC2.55
WACC7.84%
DR.CA Yearly LT Debt VS Equity VS FCFDR.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 1.79 indicates that DR should not have too much problems paying its short term obligations.
  • DR has a Current ratio of 1.79. This is amongst the best in the industry. DR outperforms 100.00% of its industry peers.
  • DR has a Quick Ratio of 1.70. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
  • With an excellent Quick ratio value of 1.70, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.7
DR.CA Yearly Current Assets VS Current LiabilitesDR.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. DR.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.96% over the past year.
  • DR shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 41.82% yearly.
  • DR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.34%.
  • Measured over the past years, DR shows a decrease in Revenue. The Revenue has been decreasing by -6.93% on average per year.
EPS 1Y (TTM)15.96%
EPS 3Y162.88%
EPS 5Y41.82%
EPS Q2Q%-16.95%
Revenue 1Y (TTM)-23.34%
Revenue growth 3Y-15.72%
Revenue growth 5Y-6.93%
Sales Q2Q%-17.54%

3.2 Future

  • DR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.70% yearly.
  • Based on estimates for the next years, DR will show a decrease in Revenue. The Revenue will decrease by -8.81% on average per year.
EPS Next Y92.77%
EPS Next 2Y-20.43%
EPS Next 3Y3.7%
EPS Next 5YN/A
Revenue Next Year-21.82%
Revenue Next 2Y-10.47%
Revenue Next 3Y-8.81%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
DR.CA Yearly Revenue VS EstimatesDR.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M
DR.CA Yearly EPS VS EstimatesDR.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

9

4. DR.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • DR is valuated reasonably with a Price/Earnings ratio of 11.45.
  • Based on the Price/Earnings ratio, DR is valued cheaper than 84.62% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.87. DR is valued rather cheaply when compared to this.
  • With a Price/Forward Earnings ratio of 5.94, the valuation of DR can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, DR is valued cheaply inside the industry as 92.31% of the companies are valued more expensively.
  • DR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 38.51.
Industry RankSector Rank
PE 11.45
Fwd PE 5.94
DR.CA Price Earnings VS Forward Price EarningsDR.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

  • DR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DR is cheaper than 100.00% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of DR indicates a rather cheap valuation: DR is cheaper than 84.62% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 5.51
EV/EBITDA 4.4
DR.CA Per share dataDR.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • DR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • DR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.12
PEG (5Y)0.27
EPS Next 2Y-20.43%
EPS Next 3Y3.7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. DR.CA Dividend Analysis

5.1 Amount

  • DR has a Yearly Dividend Yield of 2.13%.
  • Compared to an average industry Dividend Yield of 1.36, DR pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.81, DR has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.13%

5.2 History

  • The dividend of DR has a limited annual growth rate of 5.59%.
  • DR has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)5.59%
Div Incr Years0
Div Non Decr Years0
DR.CA Yearly Dividends per shareDR.CA Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • DR pays out 23.95% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of DR is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP23.95%
EPS Next 2Y-20.43%
EPS Next 3Y3.7%
DR.CA Yearly Income VS Free CF VS DividendDR.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M
DR.CA Dividend Payout.DR.CA Dividend Payout, showing the Payout Ratio.DR.CA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

DR.CA Fundamentals: All Metrics, Ratios and Statistics

MEDICAL FACILITIES CORP

TSX:DR (4/17/2026, 7:00:00 PM)

17.06

+0.19 (+1.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners8.36%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap299.40M
Revenue(TTM)254.17M
Net Income(TTM)21.26M
Analysts42.22
Price Target16.58 (-2.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.13%
Yearly Dividend0.34
Dividend Growth(5Y)5.59%
DP23.95%
Div Incr Years0
Div Non Decr Years0
Ex-Date03-31
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.13%
Min EPS beat(2)6.33%
Max EPS beat(2)35.92%
EPS beat(4)2
Avg EPS beat(4)2.44%
Min EPS beat(4)-24.98%
Max EPS beat(4)35.92%
EPS beat(8)3
Avg EPS beat(8)-21.58%
EPS beat(12)5
Avg EPS beat(12)-26.43%
EPS beat(16)7
Avg EPS beat(16)-104.25%
Revenue beat(2)1
Avg Revenue beat(2)-9.99%
Min Revenue beat(2)-21.89%
Max Revenue beat(2)1.91%
Revenue beat(4)1
Avg Revenue beat(4)-7.15%
Min Revenue beat(4)-21.89%
Max Revenue beat(4)1.91%
Revenue beat(8)2
Avg Revenue beat(8)-6.54%
Revenue beat(12)4
Avg Revenue beat(12)-4.25%
Revenue beat(16)4
Avg Revenue beat(16)-3.61%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)107.11%
EPS NY rev (3m)68.6%
Revenue NQ rev (1m)0.65%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-10.64%
Revenue NY rev (3m)-22.26%
Valuation
Industry RankSector Rank
PE 11.45
Fwd PE 5.94
P/S 0.86
P/FCF 5.51
P/OCF 4.91
P/B 2.9
P/tB N/A
EV/EBITDA 4.4
EPS(TTM)1.49
EY8.73%
EPS(NY)2.87
Fwd EY16.84%
FCF(TTM)3.1
FCFY18.16%
OCF(TTM)3.48
OCFY20.38%
SpS19.8
BVpS5.88
TBVpS-0.34
PEG (NY)0.12
PEG (5Y)0.27
Graham Number14.0382 (-17.71%)
Profitability
Industry RankSector Rank
ROA 7.8%
ROE 28.17%
ROCE 22.87%
ROIC 19.99%
ROICexc 25.4%
ROICexgc 50.53%
OM 18.36%
PM (TTM) 8.36%
GM 69.88%
FCFM 15.64%
ROA(3y)11.41%
ROA(5y)7.31%
ROE(3y)36.64%
ROE(5y)23.18%
ROIC(3y)17.04%
ROIC(5y)16.99%
ROICexc(3y)23.08%
ROICexc(5y)21.73%
ROICexgc(3y)54.96%
ROICexgc(5y)49%
ROCE(3y)19.49%
ROCE(5y)19.45%
ROICexgc growth 3Y4.72%
ROICexgc growth 5Y14.72%
ROICexc growth 3Y6.5%
ROICexc growth 5Y15.94%
OM growth 3Y8.16%
OM growth 5Y9.83%
PM growth 3YN/A
PM growth 5Y28.17%
GM growth 3Y1.88%
GM growth 5Y0.92%
F-Score5
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 1.18
Debt/FCF 2.47
Debt/EBITDA 1.43
Cap/Depr 31.15%
Cap/Sales 1.92%
Interest Coverage 9.31
Cash Conversion 71.63%
Profit Quality 187.05%
Current Ratio 1.79
Quick Ratio 1.7
Altman-Z 1.48
F-Score5
WACC7.84%
ROIC/WACC2.55
Cap/Depr(3y)47.39%
Cap/Depr(5y)41.2%
Cap/Sales(3y)3.17%
Cap/Sales(5y)2.64%
Profit Quality(3y)199%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.96%
EPS 3Y162.88%
EPS 5Y41.82%
EPS Q2Q%-16.95%
EPS Next Y92.77%
EPS Next 2Y-20.43%
EPS Next 3Y3.7%
EPS Next 5YN/A
Revenue 1Y (TTM)-23.34%
Revenue growth 3Y-15.72%
Revenue growth 5Y-6.93%
Sales Q2Q%-17.54%
Revenue Next Year-21.82%
Revenue Next 2Y-10.47%
Revenue Next 3Y-8.81%
Revenue Next 5YN/A
EBIT growth 1Y-10.18%
EBIT growth 3Y-8.84%
EBIT growth 5Y2.22%
EBIT Next Year-7%
EBIT Next 3Y-3.64%
EBIT Next 5YN/A
FCF growth 1Y-47.83%
FCF growth 3Y-7.53%
FCF growth 5Y-12.96%
OCF growth 1Y-46.4%
OCF growth 3Y-7.83%
OCF growth 5Y-12.51%

MEDICAL FACILITIES CORP / DR.CA Fundamental Analysis FAQ

What is the fundamental rating for DR stock?

ChartMill assigns a fundamental rating of 7 / 10 to DR.CA.


What is the valuation status of MEDICAL FACILITIES CORP (DR.CA) stock?

ChartMill assigns a valuation rating of 9 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.


What is the profitability of DR stock?

MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 9 / 10.


What is the valuation of MEDICAL FACILITIES CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for MEDICAL FACILITIES CORP (DR.CA) is 11.45 and the Price/Book (PB) ratio is 2.9.


How financially healthy is MEDICAL FACILITIES CORP?

The financial health rating of MEDICAL FACILITIES CORP (DR.CA) is 7 / 10.